Merck’s Keytruda may be pressuring Bristol-Myers Squibb’s Opdivo in kidney cancer in the U.S. But in England, cost watchdogs won’t be giving it the chance—at least for now. NICE shot down the combination of Merck’s star and Pfizer’s Inlyta in previously untreated patients, citing questions about its long-term benefits and its high price.
